Who are ANG-3777's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Engensis (VM202).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ang-3777.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

ANG-3777 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ANG-3777 (ANG-3777) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HGF mimetic. Area: Cardiovascular.

phase 3 HGF mimetic MET receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

ANG-3777 (ANG-3777) — Angion Biomedica Corp. ANG-3777 is a hepatocyte growth factor (HGF) mimetic that activates the MET receptor to promote tissue repair and regeneration.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ANG-3777 TARGET	ANG-3777	Angion Biomedica Corp	phase 3	HGF mimetic	MET receptor
Engensis (VM202)	Engensis (VM202)	Helixmith Co., Ltd.	phase 3	Plasmid DNA therapeutic; angiogenic agent	Hepatocyte growth factor (HGF) pathway; c-Met receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HGF mimetic class)

Angion Biomedica Corp · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ANG-3777 — Competitive Intelligence Brief. https://druglandscape.com/ci/ang-3777. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing